Metastatic Prostate Cancer

Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36 Eder IE, Culig Z, Putz T, et al. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Utol 2001; 40(3): 241–51 Bruchovsky N, Wilson JD. The conversion of testosterone to 5′-androstan-17′ol-3-one by rat prostate in vivo and in vitro. J Bioi Chem 1968; 243: 2012–7 Schroder F. Endocrine treatment of prostate cancer. In: Walsh PC, Vaughn ED, Retik A, et al., editors. Campbell’s urology. 7th ed. Philadelphia, (PA): W. B. Saunders, 1998; 3: 2627–44 Kyprianou N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol 1994; 12(6): 299–303 Sadar M, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Rel Cancer 1999; 6(4): 487–502 Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients’ choice of treatment in stage D prostate cancer. Urology 1989; 33Suppl. 5: 57–62 Robinson M, Smith P, Richards B, et al. The final analysis of the EORTC genitourinary tract cancer co-operative group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilbestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 273–83 Bishop MC. Experience with low-dose estrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996; 78: 921–8 Klotz L, McNeill I, Fleshner N, et al. A phase 1–2 trial of diethylstilibestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999; 161: 169–72 Miller JI, Ahmann FR, Drach GW, et al. The clinical usefulness of serum prostate-specific antigen after hormonal therapy of ruetastatic prostate cancer. J Urol 1992; 147: 956–61 Seidenfeld J, Samson D, Hasselblad V, et al. S ingle-therapy androgen suppression in men with advanced prostate cancer: a systematic review and roeta-analysis. Ann Intern Med 2000; 132(7): 566–77 Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973; 32(5): 1126–30 Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engi J Med 1997; 337(5): 295–300 Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectoray and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–8 The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79(2): 235–46 Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled triai of leuprolide with and without flutarnide in prostatic carcinoma. N Engi J Med 1989; 321(7): 419–24 Eisenberger M, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without fiutamide for raetastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–42 Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90(20): 1537–44 Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized triais. Lancet 2000; 355: 1474–5 Vale W, Grant G, Rivier J, et al. Synthetic polypeptide antagonist of the hypothalamic leutinizing hormone elated factor. Science 1972; 176: 933–4 McLeod D, Zinner N, Gleason D, et al. Abarelix-depot versus leuprolide acetate for prostate cancer: results of a multi-institutional, randomized phase III study in 271 patients [abstract 1306]. Proc Am Soc Clin Oncol 2000; 19: 332A Trachtenberg J, Gittelman M, Steidie C, et al. Ab arelix-depot versus leuprolide acetate plus bicalutamide for prostate cancer: results of a multi-institutional, randomized phase III study in 255 patients [abstract 1307]. Proc Am Soc Clin Oncol 2000; 19: 332A Strieker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001; 58Suppl 2A: 24–7 Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1642–5 Daniell H. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58(2A): 101–7 Bruchovsky N, Goldenberg SL, Gleave ME, et al. Intermitent therapy for prostate cancer. Endocr Rel Cancer 1957; 4: 1–25 Scher HE, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993; 11(8): 1566–72 Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11): 2511–5 Schroder FH, Collette L, de Reyke TM, et al. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for the Research and Treatment of Cancer. Br J Cancer 2000; 82: 283–90 Boccardo R, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutarnide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027–38 Brufsky A, Fontaine-Rothe P, Berlane K, et al. Finasteride and flutamide as potency-sparing androgen-albative therapy for advanced adenocarcinoma of the prostate. Urology 1995; 45: 491–7 Fleshlier NE, Trachtenberg J. Combination finasteride and flutarnide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urology 1995; 154: 1642–6 Lisle T, Mackenzie S, Ziada A, et al. Androgen deprivation therapy using finasteride and low dose flutarnide to treat PSA failure following therapy for clinically localized adenocarconoma of the prostate [abstract]. J Urology 1999; 161: 299 Ornstein DK, Rao GS, Johnson B, et al. Combined finasteride and flutarnide therapy in men with advanced prostate cancer. Urology 1996; 48: 901–5 Tannock IF, Osoba D, Stacker MR, et al. Chemotherapy with rnitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–64 Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B. J Clin Oncol 1999; 17: 2506–13 Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinbiastine plus oral estrarnustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17(10): 3160–6 Hudes GR, Nathan FE, Khater C, et al. Phase II Trial of 96 hour paclitaxel plus estramustine in metastatic hormone-refractory metastatic prostate cancer. J Clin Oncol 1997; 15: 3156–63 Hudes GR, Manola J, Conroy J, et al. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced dose oral estrarnsutine (EMP) in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 2001; 20: 697a Petryiak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estrarnustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17(3): 958–67 Hussain M, Petryiak D, Fisher E, et al. Docetaxel and estrarnustine versus rnitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Sernin Oncol 1999; 26(5 Suppl. 17): 55–60